Plan Bs' second FDA casualty

First it was the well respected Susan Wood.

Now its Frank Davidoff:

Davidoff said that FDA is favoring politics over science in delaying approval of the drug for nonprescription sales, adding, "There wasn't any observable scientific or procedural reason for them to first decline and then further delay the decision. ... [I]t seemed to me that [this] was unacceptable."

http://www.kaisernetwork.org/daily_reports/rep_index.cfm?DR_ID=32989